Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. Amy is an ACA and the CEO and founder ...

XLI vs XLF diverge in 2026 as AI/data-center capex boosts industrials while financials lag on credit and AI fears.

Lockheed Martin enters 2026 with a robust backlog, stable revenue growth, and strong free cash flow. Check out why LMT stock ...

The Tory leader says the student loan system is at "breaking point" as the PM says his government will "look at ways to make ...

Make a festive Easter Bunny Bread Bowl with your favorite dip—an easy, fun appetizer idea that saves time & wows guests. Read ...

A new AI note taking tool called Abridge is transforming medical visits for patients and their providers. Doctors now can ...

Explore expert analysis and forecasts for NEAR's future price movement. Get the latest price prediction after the super app ...

What does it take to build a company that lasts? For three St. Louis executives celebrating significant business anniversaries, the answer lies in adapting early, investing in people and staying ...

Bruno, Fx, ActivityWatch, DDEV, and TLDR Pages are all dev tools that you should try out because they're much better than ...

The latest rate, which covers the year to January, is a drop from the previous 3.4% - but it remains above the Bank of ...

Objective To assess whether post-authorisation studies registered with the European Medicines Agency (EMA) adhere to legislation and recommendations to publicly post study protocols and results.